Safety of pregabalin among hemodialysis patients suffering from uremic pruritus

Tahir Mehmood Khan a,*, Abdul Aziz Alhafez b, Syed Azhar Syed Sulaiman c, David Wu Bin Chia a

a School of Pharmacy, Monash University, Bandar Sunway, 45700 Selangor, Malaysia
b Director, Aljaber Kidney Center, Eastern Province, Alahsa, Saudi Arabia
c School of Pharmaceutical Sciences, University Sains Malaysia 11800, Pulau Pinang, Malaysia

Received 20 August 2014; accepted 30 October 2014
Available online 24 January 2015

Abstract  Objectives: The aim of this study was to assess the safety and probability of adverse events associated with the use of 75 mg pregabalin post hemodialysis (pHD) among patients with UP. Methods: A cross-sectional study done among the hemodialysis patients suffering from uremic pruritus (UP) Aljaber Kidney Center (AJKC), Al-Ahsa, Eastern Province, Saudi Arabia. Assessment for the safety profile of pregabalin was done using Naranjo’s algorithm. A predictive model was developed using binary multiple logistic regression to explore association of patients’ demographics and risk factors with the occurrence of AEs. Throughout statistical significance level was considered significant at 0.05. Key findings: Assessment of safety of pregabalin revealed that somnolence and dizziness were the two frequent adverse events followed by constipation, weight gain and edema. However, it was noticed that female patients aged less than 50 years were found to be at a higher risk in comparison with men. Moreover, those patients having one comorbid complication (i.e. hypertension or diabetes mellitus alone) were at a higher risk of somnolence, weight gain and dry mouth. Conclusion: Naranjo’s quantification for the possibility and probability of adverse events reflect that all the events were probable. Age, gender and comorbid medical conditions are some of the factors that might have clinical association with the occurrence of the AEs.

1. Introduction

Uremic pruritus (UP) is one of the most common complications faced by patients with end stage renal disease (ESRD) (Denman, 1986; Goicoechea et al., 1999; Greaves, 2005; Hiroshige and Kuroiwa, 1996; Kfoury and Jurdi, 2012). Due to complex pathophysiology of disease, variety of drugs such as anti-histaminic, opioids agonist, emollients, antidepressants and neuroleptic drugs are tested to provide relief to the ESRD...
suffering through UP (Alomar et al., 2008; Anand, 2013; Andersen et al., 1984; Aramwit et al., 2012; Balaskas et al., 1998; Begum et al., 2004; Breneman et al., 1992; Cho et al., 1997; De Marchi et al., 1992; Lin et al., 2012; Peck et al., 1996; Schmitz et al., 2002). In most of the cases relief from UP was short term and patients have suffered the consequences in the form of relapse to UP. However, recent studies that has tested pregabalin (PG), provided evidence of promising relief to the patients suffering from treatment resistant UP. Shavit et al., (2013) have reported on the therapeutic effectiveness of pregabalin 25–50 mg/day among UP patients showing resistance to antihistamines and emollients (Shavit et al., 2013). In addition other studies have also reported on the effectiveness of pregabalin 25 mg/day among ESRD patients with treatment resistance pruritus (previously tested for emollients, antihistaminic and UV light) (Aperis et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al., 2013; Solak et al., 2012).

Addressing the safety profile of the pregabalin the drug development data reflect the pregabalin safety among health population and till to date there is limited safety data for pregabalin among ESRD patients (Pregabalin, 2009). Recent case studies and case series have reported some adverse events that were found associated with the use of pregabalin among patients with treatment resistant pruritus (previously tested for emollients, antihistaminic and UV light) (Aperis et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al., 2013; Solak et al., 2012). However, the significance and probability of these events is not yet tested using any algorithm that assist in quantifying the significance/probability of these events. Naranjo’s algorithm is widely used globally in order to test the probability/significance of a drug related event (Khan et al., 2013; Naranjo et al., 1981; Smyth et al., 2012).

For a drug like pregabalin that is renally cleared, it is very essential to estimate its safety profile when it is considered to be used among ESRD patients. Till to date there is a scarcity of any evidence for the safety and efficacy of pregabalin among ESRD patient from Arab region. The current study will address this issue using a cross-sectional study design to observe the severity and probability of adverse events that are associated with the use of pregabalin among hemodialysis (HD) patients suffering from UP.

2. Methodology

This was cross-sectional study done among the hemodialysis patients suffering from UP and receiving HD at Aljaber Kidney Center (AJKC), Al-Ahsa, Eastern Province, Saudi Arabia. AJKC is the only public dialysis center in Al-Ahsa offering medical services to patients with ESRD. It is operated under the directorate of Health Services, Ministry of Health, Saudi Arabia. “Al-Ahsa” is the Arabic word for “oasis,” and Al-Ahsa is perhaps the largest oasis in Saudi Arabia. It is known to be the oldest trade route for merchants in the Gulf region and is the only oil-producing province in Saudi Arabia. The majority of the population resides in three main areas: Al-Hufuf, Al-Dammam and Al-Mubarraz. Nearly 70–80% of Al-Ahsa residents are Saudi natives, followed by expatriates from different parts of world. The remaining population is scattered throughout approximately 50 small villages surrounding Al-Hufuf, Al-Dammam and Al-Mubarraz (Al-Hasa, 2013).

2.1. Study population

A total of 314 patients are registered for dialysis at AJKC. These patients are managed in three shifts: morning, afternoon and evening. Of the total number, 173 are male patients and 112 are female patients. Of whom N = 285 patients are on HD while the rest are on peritoneal dialysis. On average, about 130 patients are dialyzed on daily basis. Patients visiting for dialysis during the morning shift were assessed for their potential enrollment in this study. The assessment of severity and intensity of UP was done using a validated version of 5D-itching scale (Khan et al., 2013). The first line treatment at AJKC for UP is loratadine 10 mg daily for two month alone or in combination with Vaseline lotion as an emollient. If the UP persists, then the consultant can recommend pregabalin 75 mg to manage the severity of UP. Furthermore, to ensure the patient safety in advance, a safety assessment protocol was developed to rule out the patients that should not be prescribed pregabalin or monitored closed due to a higher risk of adverse events (AEs) (Khan et al., 2014). Upon screening of the records N = 51 patients were found taking pregabalin 75 mg post hemodialysis (pHD) throughout the study duration [April 1, 2012, through May 28, 2013].

2.2. Interpretation and analysis of AEs

In order to make the interpretation of AEs more effective and in line with the evidence-based literature, Naranjo’s algorithm, known to be a valid measure for reporting and authenticating drug-related events, was applied (Kathleen et al., 2003; Naranjo et al., 1981). Naranjo’s algorithm is a ten-item scale with three options (“yes,” “no,” and “don’t know”) to express the occurrence of a drug-related incident. Based on these three options, a score is assigned for each item. If the total score is of more than 9, it reflects that the AEs are due to the drug being used by the patient. A probable drug-related AE is assumed if the score is between 5 and 8, and a possible drug-related AE is assumed when the score is between 1 and 4. If the score is 0, it indicates that the AE is not due to the drug in use, but other factors. Details about the items and scoring pattern for the Naranjo’s algorithm are shown Table 2. All the patients completing 42 days of pregabalin therapy were questioned about any AEs that they may have experienced after taking pregabalin. The information was collected based on the patients experience and the list of the AEs mentioned in Table 2 (Lyrica, 2013). Naranjo’s algorithm was used to estimate the possibility of an association between these events and pregabalin use.

2.3. Data analysis for the interpretation of adverse events

Possible AEs were listed on a separate data collection form and were documented based on patient responses. Physician and nursing staff support were used to interpret patients’ experiences in order to assess the incidence of any of the AEs. Descriptive statistics were applied to calculate scores based on Naranjo’s algorithm. A standard scoring pattern was adopted to quantify the possible association between the AEs and pregabalin use (Kathleen et al., 2003; Naranjo et al., 1981). Total scores range from –4 to +13; if the score is 9 or more than the AE is considered as definite, probable if 5–8, possible if 1–4, and doubtful if 0 or less (Kathleen et al., 2003).
et al., 2003; Naranjo et al., 1981). Furthermore, a predictive model was developed using binary multiple logistic regression to explore association of patients’ demographics and risk factors with the occurrence of AEs. Overall, six predictive models were built for six AEs, respectively. Throughout statistical significance level was considered significant at 0.05.

2.4. Ethics approval

The study protocol was approved by institutional authorities: the college of clinical pharmacy, deanship of scientific research and Al-Jaber Kidney Dialysis Center (AKD)/King Fahad hospital in Al-Ahsa, Saudi Arabia.

3. Results

Upon initial safety screening, fifty one patients were found to be the potential candidates for the pregabalin therapy. Overall, most of the patients that were selected after safety assessment were from the age group 40–70 years [Mean = 55.54 yrs ± SD 13.29, Median = 55 yrs]. Majority of the patients 36 (70.6%) were male, and 48 (94.1%) were married. In terms of education most of them having primary education, followed by high school/college and Islamic education. While investigating the occupational status it was revealed that 20 (39.2%) of the patients were government employees and about 17 (33.3%) were jobless (Table 1).

3.1. Assessment for AEs

The assessment for the safety of pregabalin was done using the manufacturer guide for the patients who have taken pregabalin for the duration of 6 weeks or more. Overall, Dizziness was reported by 47.0% of the patients followed by somnolence 22 (43.1%), constipation 15 (29.4%), blurred vision 10 (19.6%), weight gain 6 (11.8%) and edema 5 (9.8%) dry mouth 3 (5.9%). However, in some cases it was difficult to rule out the associate of an event with the pregabalin use, because some of the patients they reported that they were facing such complication from last two months or more (e.g. dry mouth, edema and headaches). Moreover in some case for example weight gain, it was hard to conclude that either the variations are due to pregabalin or due to the ESRD. Therefore weight gain was only associated with pregabalin in the case when the increase is more than 5.0 kg in comparison with their baseline assessment. In the case where is a risk of doubt, such incidence was ranked as undecided (Table 2).

For the confirmed AEs Naranjo’s algorithm was applied to estimate the possibility of an association of the event with pregabalin use. Upon calculation of the score it was revealed that weight gain and edema (score = 4) have a possible association with the administration of pregabalin. While somnolence, blurred vision, dysarthria, and constipation were found to have probable association with the administration of pregabalin (score = 4). Details are shown in Table 3.

Furthermore, to assess the possible association among AEs with the age, gender and comorbidities were assessed using binary multiple logistic regression model. Overall, no statistically significant association was observed. However, it was noticed that female patients aged less than 50 years were found to be at a higher risk in comparison with men. Moreover, those patients having one comorbid complication (i.e. hypertension or diabetes mellitus alone) were at a higher risk of somnolence, weight gain and dry mouth. Details are shown in Table 4.

4. Discussion

Assessment of the AEs is one of the important aspects of drug safety, which is always preferred by the clinician before approving a drug for the patient with lifelong disease conditions or with compromised organ functions. Recent studies exploring the safety of pregabalin reported a variety of AEs among the patients (Zuccara et al., 2011). Perucca et al. (2009) stated that the AEs of pregabalin may reduce the quality of life of patients (Perucca et al., 2009). Overall, the common AEs reported were associated with 'cognition/
coordination" and severely reduced the quality of life among the patients (Liao et al., 2008; Nakagawasai et al., 2010; Perucca et al., 2009; Zhuchenko et al., 1997). Common AEs that were observed among the pregabalin users were dizziness, vertigo, incoordination, balance disorder, ataxia, tremor, diplopia, blurred vision, euphoria, poor or lack of attention, abnormal thinking, somnolence, confusion, asthenia, fatigue and amblyopia. Ben-Menachem (2004) associated the inhibition of depolarization-dependent influx as the main reason for the decreased neurotransmitter release (Porter et al., 2004; Ben-Menachem, 2004). Therefore, alterations in the normal levels of neurotransmitters in the central nervous system will lead to these AEs, which increase in severity with increased dose (Liao et al., 2008; Porter et al., 2004; Zhuchenko et al., 1997). Moreover, the other AEs, including edema, peripheral edema, dry mouth and constipation, were not found to be associated with increased dose (Zaccara et al., 2011).

However, the study population of the current study was different from the samples of previous studies addressing safety of pregabalin (Liao et al., 2008; Nakagawasai et al., 2010; Perucca et al., 2009; Porter et al., 2004; Zhuchenko et al., 1997). Therefore, the likelihood of the AEs that were dose dependent was less. Randinitis et al. (2003) have shown pharmacokinetic justifications that limit the dose of pregabalin to 75 mg per day for patients with compromised renal function (Randinitis et al., 2003). Most of the recent case reports and cross-sectional studies that have studied the effect of pregabalin in refractory pruritus among ESRD patients have used a dose of 25–75 mg per day and, in most cases, the effect and safety of pregabalin were observed after 4 weeks (Aperis et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al., 2013; Solak et al., 2012). Among ESRD patients, the common AEs observed were dizziness, somnolence and over-sedation. Similar to the findings of Aperis et al. (2010), Rayner et al. (2012) and Solak et al. (2012), somnolence and dizziness were the frequent adverse event presented by the majority of the patients. Moreover, other AEs were constipation (29.4%), weight gain (11.8%) and edema (9.8%). However, in some cases, some of the AEs were hard to rule out, and were therefore considered “undecided”. Certain complications, including weight gain and edema, are also associated with the ESRD itself, and the patients’ medical records show frequent variations in the weight and fluid accumulation among the patients (Chamney et al., 2002). Therefore, in the case where patients had frequent variation in weight and fluid accumulation, the benefit of the doubt was given to pregabalin and the incidence of such events was marked as undecided. However, the probability of AEs was not confirmed through the Naranjo algorithm for weight gain (score = 4) and edema (score = 4). Somnolence, dizziness, blurred vision, dysarthria and constipation were found to be probable AEs due to pregabalin use.

### Table 3: Assessment of itching distribution on day forty two.

| AEs                  | Confirm N (%) | Score based on Naranjo’s algorithm | AEs assessment based on Naranjo’s algorithm |
|----------------------|--------------|-----------------------------------|---------------------------------------------|
| Somnolence           | 22(43.1%)    | 7                                 | Probable                                   |
| Dizziness            | 24(47.0%)    | 7                                 | Probable                                   |
| Blurred vision       | 10(19.6%)    | 7                                 | Probable                                   |
| Dry mouth            | 3(5.9%)      | 7                                 | Probable                                   |
| Constipation         | 15(29.4%)    | 7                                 | Probable                                   |
| Weight gain          | 8(11.8%)     | 4                                 | Possible                                   |
| Edema                | 5(9.8%)      | 4                                 | Possible                                   |

### Table 4: Variables associated with the AEs.

| Adverse event | Variables | OR (CI-95%) | p-Value |
|---------------|-----------|-------------|---------|
| Somnolence    | Age (< 50 years) | 0.981[0.941–1.022] | 0.349   |
|               | Gender (female) | 1.656[0.476–5.766] | 0.428   |
|               | Comorbidities (1 CM) | 1.340[0.394–4.561] | 0.639   |
| Vision disturbances | Age (< 50 years) | 1.025[0.283–3.710] | 0.969   |
|               | Gender (female) | 1.014[0.974–1.056] | 0.496   |
| Dry mouth     | Age (< 50 years) | 0.971[0.908–1.037] | 0.381   |
|               | Gender (female) | 0.842[0.134–5.297] | 0.855   |
|               | Comorbidities (1 CM) | 6.107[0.587–9.592] | 0.130   |
| Constipation  | Age (< 50 years) | 0.956[0.915–0.998] | 0.041   |
|               | Gender (female) | 0.694[0.194–2.485] | 0.574   |
| Weight gain   | Age (< 50 years) | 0.964[0.900–1.033] | 0.298   |
|               | Gender (female) | 0.710[0.110–4.574] | 0.718   |
|               | Comorbidities (1 CM) | 1.907[0.266–13.669] | 0.521   |
| Edema         | Age (< 50 years) | 0.974[0.908–1.045] | 0.458   |
|               | Gender (female) | 1.207[0.162–8.974] | 0.854   |

Warning(s) entered on step 1: Age, gender and Comorbidities.  
CM = Comorbidity.  
* p-Value < 0.05
In the current sample, it is hard to associate the genetic element with the incidence of AEs observed after pregabalin use. Two main challenges hinder a valid conclusion in this regard: one is the lack of a safety profile of pregabalin among Arabs, and the second is the deficient pharmacokinetic profile among patients with ESRD. Therefore, it is possible that the genetic composition of the current sample is one of the factors that may have augmented the chance of AEs, such as somnolence and dizziness, in the current sample, and perhaps due to this reason, the incidence of these events was double when compared to other studies that investigated the use of pregabalin among UP patients (Aperis et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al., 2013; Solak et al., 2012). Moreover, other AEs including constipation (29.4%), weight gain (11.8%) and edema (9.8%) were only observed in the current sample, and it can be assumed that genetic factors might be one of the influencing factors that provoke the AEs that were not observed by other studies (Aperis et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al., 2013; Solak et al., 2012). Along with the genetic issues, ESRD itself can be one of the reasons for the events such as dizziness, headaches, dry mouth, somatic symptoms and somnolence (Brown and Gower, 1982; NHS, 2013). However, keeping in mind the scarcity of evidence in this regard, the ability of the current study to draw a solid conclusion about the association of genetics with the AEs observed is limited. Future research among ESRD patients and non-ESRD patients will be helpful in providing evidence to determine the association of genetics with the AEs observed with pregabalin use.

Particularly addressing the gastrointestinal (GIT) complications associated with the use of pregabalin, it was noted that about 17 (33.4%) patients were taking lactulose before starting pregabalin therapy. In other words, it can be stated that 33.4% of the patients had GIT symptoms, i.e. constipation before using the pregabalin, which is a common complication faced by most of the ESRD patients that are on HD (Singharetarnam and Holley, 1996; Wu et al., 2004; Yasuda et al., 2002). Most of HD patients are on oral iron supplementation. Oral iron consumption is reported to be a known reason for the GIT complications, such as constipation, among normal patients and those with ESRD (Suh and Wadhwa, 1992; Van Wyck et al., 2005). Thus concurrent use of iron with ESRD itself has a major role in resulting GIT complications, including constipation. However, based on the Naranjo algorithm, it seems that constipation is associated with the use of pregabalin. Though, in the presence of confounders, including prior episodes of constipation before starting pregabalin and concurrent use of iron during ESRD, it might be clinically difficult to prove a significant associate of constipation with the pregabalin administration.

By exploring the association of other AEs with the demographics and comorbidities using a multiple logistic regression model, it was revealed that visual disturbances were more common among the male patients with odds ratio of 1.014 [95% CI: 0.974–1.056] compared to female ones. Moreover, about 24 (47.1%) of the patients had diabetes mellitus, which is a known cause of visual complications among the patients (Lee et al., 1997; Nakamura et al., 2005). In addition, the majority of the patients in the current sample were aged more than 50 years, which is in line with the increased risk with odds ratio of 1.025 [95% CI: 0.283–3.710] in our predictive model for the visual complications among the current sample. Furthermore, it is possible that administration of pregabalin might have worsened the visual acuity of the patients. However, it is noteworthy that although the statistical significance was not observed in the current predictive model, our regression-based approach is useful to control for all potential risk factors to obtain better precision.

5. Conclusion

Naranjo’s quantification for the possibility and probability of AEs is a beneficial measure to rule out the possibility and probability of AEs. AEs observed in this study were moderate in nature and well tolerated by the patients. Age, gender and comorbid medical conditions are some of the factors that might have clinical association with the occurrence of the AEs.

6. Clinical implications

Overall, the findings of the current study reflect that pregabalin is safe for use among ESRD patients. That is why there were no dropouts, unlike other studies that have used pregabalin to treat UP (Aperis et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al., 2013; Solak et al., 2012). Moreover, an initial safety assessment before starting pregabalin can be an effective measure to monitor the patients that might be at a higher risk of AEs (Khan et al., 2014). Thus, in cases where pregabalin is contraindicated or may complicate the patient’s situation, such cases should be identified in advance and monitored closely or considered for alternative treatment options.

7. Limitations of study

The current study was an observational study addressing the safety of Pregabalin among patients with treatment resistant pruritus. Due to the ethical and regulatory reason, it was not possible to allocate a control group for the effective comparison.

8. Recommendations for future research

The time duration of current study was small, assessment for safety was done on day 42 and there was no longitudinal data available to estimate the long term effect of drug. Future studies planning to address the same issue should consider adopting a longitudinal study design to estimate the safety profile of pregabalin in long run.

Acknowledgment

We would like to acknowledge the continuous support from Dr. Ibrahim Alhaider, Dean college of clinical pharmacy, King Faisal University, Alahsa, Saudi Arabia.

References

Al-Hasa, 2013. Saudi Arabia, Encyclopedia Britannica Online. <http://www.britannica.com/EBchecked/topic/256446/Al-Hasa>. 
Alomar, A., Corella, F., Garcia-Navarro, X., 2008. Tacrolimus in diseases other than atopic dermatitis. Actas Dermosifiliogr 99 (Suppl 2), 26–35.

Anand, S., 2013. Gabapentin for pruritus in palliative care. Am. J. Hosp. Palliat. Care 30 (2), 192–196. http://dx.doi.org/10.1177/1049901112445464.

Andersen, L.W., Friedberg, M., Lokkegaard, N., 1984. Naloxone in the treatment of uremic pruritus: a case history. Clin. Nephrol. 21 (6), 355–356.

Aperis, G., Paliouras, C., Zervos, A., Arvanitis, A., Alivianis, P., 2010. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. J. Ren. Care 36 (4), 180–185. http://dx.doi.org/10.1111/j.1755-6686.2010.00190.x.

Aramwit, P., Asydhan, O., 2012. Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrol. 13, 119. http://dx.doi.org/10.1186/1471-2369-13-119.

Balaskas, E.V., Bamihas, G.I., Karamouzis, M., Voyiatzis, G., Tourkantonis, A., 1999. Histamine and serotonin in uraemic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 78 (4), 395–402.

Ben-Menachem, E., 2004. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45 (Suppl 6), 13–18.

Begum, R., Belury, M.A., Burgess, J.N., Peak, L.W., 2004. Supplementation with n-3 and n-6 polyunsaturated fatty acids: effects on lipoxigenase activity and clinical symptoms of pruritus in hemodialysis patients. J. Ren. Nutr. 14 (4), 233–241.

Breneman, D.L., Cardone, J.S., Blumsack, R.F., Lather, R.M., Searle, E.A., Pollack, V.E., 1999. Topical capsaicin for treatment of hemodialysis-related pruritus. J. Am. Acad. Dermatol. 26 (1), 91–94.

Brown, E.A., Gower, P.E., 1982. Joint problems in patients on maintenance hemodialysis. Clin. Nephrol. 18 (5), 247–250.

Bockbrader, H.N., 2003. Pharmacokinetics of pregabalin in subclinical organ transplant patients. J. Am. Acad. Dermatol. 58 (2 Suppl), S36–S37. http://dx.doi.org/10.1016/j.jaad.2007.07.017.

Boitnott, J.K., 1984. Erythromelalgia: clinical and cutaneous considerations. J. Am. Acad. Dermatol. 10 (1), 53–60.

Bottiglieri, T., 2011. N-type calcium channels in the pathophysiology of the dermatologic disorders. Coord. Chem. Rev. 255 (13–14), 1559–1575. http://dx.doi.org/10.1016/j.ccr.2011.06.001.

Boyn, S., Hensman, Y., Wizemann, V., 2002. A new technique for defining the skin thickness in patients with various degrees of renal function. J. Clin. Pharmacol. 43 (4), 375–392.

Brinkmann, V., Kopp, S., Sontheimer, H.J., 2004. Neutrophil extracellular traps: a novel antimicrobial mechanism. J. Clin. Invest. 114 (8), 1113–1119. http://dx.doi.org/10.1172/JCI21808.

Buck, D.J., Fotin, A.D., Cook, J.A., Bockbrader, H.N., 2003. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43 (3), 277–283.

Budde, K., 2005. Dialysis and pruritus: current concepts and future perspectives. J. Nephrol. 18 (4), 323–334. http://dx.doi.org/10.1007/s12623-005-0004-5.

Buckley, K., Quirk, J.P., Slaughter, P.D., 2004. Uremic pruritus in haemodialysis patients. J. Ren. Care 36 (4), 261–266. http://dx.doi.org/10.1111/j.1365-2702.2011.03906.x.

Lyrica, 2013. Prescriber Product Information Pfizer. <http://labeling.pfizer.com/ShowLabeling.aspx?id=561>.

Nakagawasaki, O., Onogi, H., Mizutani, S., Sato, A., Watanabe, K., Saito, H., Todo, T., 2010. Behavioral and neurochemical characterization of mice deficient in the N-type Ca\(^{2+}\) channel alpha1B subunit. Behav. Brain Res. 208 (1), 224–230. http://dx.doi.org/10.1016/j.bbr.2009.11.042.

Nakamura, Makoto, Kanamori, Akiyasu, Negi, Akira, 2005. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica 219 (1), 1–10.

Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., Greenblatt, D.J., 1981. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30 (2), 239–245.

NHS, 2013. Dialysis – Side Effects. <http://www.nhs.uk/Conditions/DialysisPages/Side-effects.aspx>.

Peck, L.W., Monsen, E.R., Ahmad, S., 1996. Effect of three sources of long-chain fatty acids on plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am. J. Clin. Nutr. 64 (2), 210–214.

Perucca, P., Carter, J., Vahle, V., Gilliam, F.G., 2009. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 72 (14), 1223–1229. http://dx.doi.org/10.1212/01.wnl.0000345667.45642.61.

Porter, B.E., Maronski, M., Brooks-Kayal, A.R., 2004. Fate of newborn dentate granule cells after early life status epilepticus. Epilepsia 45 (1), 13–19.

Pregabalin, 2009. MedlinePlus Drug Information. U.S National Library of Medicine. <http://www.nlm.nih.gov/medlineplus/druginfo/meds/a605045.html>.

Randini, E.J., Posvar, E.L., Alvey, C.W., Sedman, A.J., Cook, J.A., Bockbrader, H.N., 2003. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43 (3), 277–283.

Rayner, H., Baharani, J., Smith, S., Suress, V., Dasgupta, I., 2012. Uraemic pruritus: relief of itching by gabapentin and pregabalin. Nephron Clin. Pract. 122 (3–4), 75–79. http://dx.doi.org/10.1159/000349493.

Schmitz, P.G., McCloud, L.K., Reikes, S.T., Leonard, C.L., Gellens, M.E., 2002. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J. Am. Soc. Nephrol. 13 (1), 184–190.

Shavit, L., Grenader, T., Lifschitz, M., Slotki, I., 2013. Use of pregabalin in the management of chronic uraemic pruritus. J. Pain Symptom. Manage. 45 (4), 776–781. http://dx.doi.org/10.1016/j.jpainsymman.2012.03.001.

Singharetunam, W., Holler, J.L., 1996. Acute treatment of constipation may lead to transmural migration of bacteria resulting in gram-negative, polymicrobial, or fungal peritonitis. Perit. Dial. Int. 16 (4), 423–425.
Smyth, R.M., Gargon, E., Kirkham, J., Cresswell, L., Golder, S., Smyth, R., Williamson, P., 2012. Adverse drug reactions in children – a systematic review. PLoS ONE 7 (3), e24061. http://dx.doi.org/10.1371/journal.pone.0024061.

Solak, Y., Biyik, Z., Atalay, H., Gaipov, A., Guney, F., Turk, S., Kanbay, M., 2012. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) 17 (8), 710–717. http://dx.doi.org/10.1111/j.1440-1797.2012.01655.x.

Suh, H., Wadhwa, N.K., 1992. Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv. Perit. Dial. 8, 464–466.

Van Wyck, David, B., Roppolo, Michael, Martinez, Carlos, O., Mazey, Richard, M., McMurray, Stephen, 2005. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 68 (6), 2846–2856.

Wu, Ming-Ju, Chang, Chi-Sen, Cheng, Chi-Hung, Chen, Cheng-Hsu, Lee, Wen-Chin, Hsu, Yu-Huang, Tang, Ming-Jer, 2004. Colonic transit time in long-term dialysis patients. Am. J. Kidney Dis. 44 (2), 322–327.

Yasuda, Gen, Shibata, Kazuhiko, Takizawa, Ikeda, Yumiko, Tokita, Yasuo, Umemura, Satoshi, Tochikubo, Osamu, 2002. Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am. J. Kidney Dis. 39 (6), 1292–1299.

Zaccara, Gaetano, Gangemi, Pierfranco, Perucca, Piero, Specchio, Luigi, 2011. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 52 (4), 826–836. http://dx.doi.org/10.1111/j.1528-1167.2010.02966.x.

Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D.W., Amos, C., Lee, C.C., 1997. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 15 (1), 62–69. http://dx.doi.org/10.1038/ng0197-62.